Angiofibroma

03/01/2023 - "Topical rapamycin can be considered an effective and safe option for the treatment and the prevention of facial angiofibromas in younger patients, but the best formulation has yet to be established. "
01/01/2018 - "Clinically meaningful and statistically significant improvement in facial angiofibromas was observed for both 1% and 0.1% rapamycin relative to the vehicle-only control group, and for 1% vs 0.1% rapamycin, with most of the improvement realized within the first month. "
01/01/2015 - "Topical rapamycin can be considered a safe option for the treatment and the prevention of facial angiofibromas in younger patients, but the best formulation has not been established. "
03/31/2022 - "The NMA found when compared with placebo, facial angiofibromas significantly improved following the application of various concentrations of topical sirolimus (risk ratio being 3.87, 2.70, 4.43, and 3.34 for 0.05%, 0.1%, 0.2%, and 1%, respectively). "
07/01/2014 - "Sirolimus has been shown to be beneficial in treating facial angiofibromas. "

01/28/2008 - "These findings could lead to a novel treatment approach for facial angiofibromas and other TSC skin lesions."
03/31/2022 - "We included three trials on 261 TSC patients with facial angiofibromas. "
02/01/2012 - "Although larger studies are needed, this treatment shows a potential to be a first-line management for facial angiofibromas in TSC and appears safe to start in early childhood."
01/01/2023 - "The mosaic variant allele frequency (VAF) is significantly higher in TSC1 than in TSC2, in both blood and saliva (median VAF: TSC1, 4.91%; TSC2, 1.93%; p = 0.036) and facial angiofibromas (median VAF: TSC1, 7.7%; TSC2 3.7%; p = 0.004), while the number of TSC clinical features in individuals with TSC1 and TSC2 mosaicism was similar. "
01/01/2023 - "The patient's mother exhibited facial angiofibromas, a common feature of TSC. "

03/31/2022 - "To assess the effects of topical mTOR inhibitors in treating facial angiofibromas, we conducted a systematic review and network meta-analysis (NMA) and searched MEDLINE, Embase, and Cochrane Library for relevant randomized controlled trials on 14 February 2022. "
03/01/2019 - "Topical mTOR inhibitors were significantly more efficient than placebo for angiofibromas (relative risk, 2.52; 95% confidence interval, 1.27-5.00; I2 = 0%). "
01/01/2016 - "Currently available clinical data suggest that topical application of mTOR inhibitors may be effective in the treatment of facial angiofibromas associated with tuberous sclerosis complex. "
03/01/2023 - "Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update."
08/01/2011 - "Evidence supports and ongoing studies are evaluating the role of mTOR inhibitors in the treatment of a wide spectrum of disease manifestations, including reduction in tumor volume (SEGAs, renal angiomyolipoma) and improvement in epilepsy, lung function and skin manifestations, including facial angiofibromas. "

07/01/2014 - "For patients who suffer from disfiguring facial angiofibromas only, there is a need for a topical use of mammalian target of rapamycin inhibitors. "
01/01/2014 - "Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?"
10/01/2019 - "Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment. "
01/01/2014 - "A germline mutation of the TSC1 or TSC2 gene, leading to activation of the mammalian target of rapamycin (mTOR) pathway, accounts for the pathogenesis of TSC-associated angiofibromas. "
01/01/2008 - "In addition, recent clinical trials using inhibitors of the mammalian target of rapamycin (mTOR) have demonstrated regression of astrocytomas, angiofibromas, and angiomyoliomas, as well as improved pulmonary function in persons with TSC."

01/01/2017 - "Sirolimus ointment 0.1% administered once a day was effective in treating facial angiofibromas. "
01/01/2018 - "0.2% sirolimus ointment is safe and effective for facial angiofibromas. "
01/01/2017 - "The impact of sirolimus ointment was monitored with digital photography, dermatological review using a validated Facial Angiofibroma Severity Index (FASI), and quality of life assessments using the questionnaires PedsQL for children and SF36 for adults. "
07/01/2014 - "We present a 10-year-old girl whose facial angiofibromas were successfully treated with an everolimus ointment without relevant side effects. "
10/01/2018 - "Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy."

07/01/2014 - "Topical everolimus seems to be a favorable and safe option for patients with facial angiofibromas who do not require systemic treatment."
07/01/2014 - "Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. "
01/01/2013 - "Improvements in SEGA size, facial angiofibromas, seizures, and the most stable low rates of self-injury were observed during the interval of treatment with everolimus. "
01/01/2021 - "The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma."
07/01/2014 - "But the topical use of everolimus, which has the approval to treat tuberous sclerosis complex-associated tumors, namely giant cell astrocytomas and renal angiofibromas, has not been reported. "

09/01/2023 - "A Narrative Review of Flutamide in Juvenile Nasopharyngeal Angiofibroma."
12/01/2018 - "A 15-year-old male with a prior diagnosis of juvenile nasopharyngeal angiofibroma stage IIIB on preoperative flutamide for 3.5 weeks presented with altered sensorium, meningeal signs, and clear watery nasal discharge consistent with CSF leak. "
04/01/2004 - "Flutamide as a preoperative treatment in juvenile angiofibroma (JA) with intracranial invasion: report of 7 cases."
06/01/1992 - "Flutamide-induced regression of angiofibroma."
11/01/2022 - "Flutamide may be an effective neoadjuvant therapy in some cases of juvenile nasopharyngeal angiofibroma, but larger scale, case-control studies are likely needed to further expand on this conclusion. "

10/01/2022 - "Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex."
09/01/2015 - "Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel."
09/01/2015 - "Here we present an exploratory case report of a patient with tuberous sclerosis complex who had significant clinical improvement of her facial angiofibromas utilizing a "split-face" comparison protocol of topical timolol 0.5% gel after full-field treatment with ablative fractional laser resurfacing and pulsed-dye laser."
10/01/2022 - "This study aimed to assess the efficacy and safety of topical timolol in treating facial angiofibromas (FAs) in pediatric patients with tuberous sclerosis complex (TSC). "

01/01/1986 - "Three patients with extensive facial angiofibromas were treated successfully with the carbon dioxide (CO2) laser, with follow-up period ranging from 8 to 48 months. "
11/01/2016 - "We present our experience of treatment of angiofibromas using carbon dioxide (CO2) laser ablation and provide a timely literature review. "
11/01/2001 - "Four female patients between 12-22 years in age with extensive angiofibromas on face, nasolabial folds and chin for 2-10 years were treated with carbon dioxide (CO2) laser. "
11/01/2001 - "Extensive facial angiofibromas in tuberous sclerosis treated with carbon dioxide laserbrasion."
08/01/2002 - "Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis."

01/21/2022 - "The patient presented with facial angiofibromas, epilepsy, fibrous plaques, periungual fibroma, renal angiomyolipomas (AML), pulmonary lymphangioleiomyomatosis (LAM), liver hamartomas, and osteosclerosis. "
03/01/2023 - "Two individuals previously thought to have sporadic LAM were diagnosed with mosaic TSC-associated LAM upon next-generation sequencing of unilateral angiofibromas in one and an unusual cutaneous hamartoma in the other. "
09/23/2022 - "She was diagnosed with renal AML and pulmonary LAM along with facial angiofibromas as well as tuberous sclerosis complex (TSC), although she had no TSC1 or TSC2 gene mutations. "
01/01/2011 - "We observed regression of brain tumors (SEGAs) in 7/11 cases (26% mean decrease in diameter), regression of liver angiomyolipomas in 4/5 cases (32.1% mean decrease in longest diameter), subjective improvement in facial angiofibromas in 57%, and stable lung function in women with TSC/LAM (n = 15). "
03/01/2017 - "Affected patients may present early in life with the classic triad of seizures, intellectual disability, and cutaneous angiofibromas, but some findings, notably renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM);, emerge later, placing adults with undiagnosed TSC at increased risk for morbidity and mortality. "

04/01/2007 - "We are herewith reporting a case of nasopharyngeal angiofibroma who showed complete hemostasis and improvement in vision to radiotherapy."
02/01/2019 - "Recent evidence on the behavior of residual postoperative juvenile angiofibroma and the development of conformal RT techniques have helped to clarify the role of watchful waiting and radiotherapy (RT) as alternatives to aggressive procedures in cases with critical extension of the lesion. "
05/01/2010 - "[Efficacy of radiotherapy on residual nasopharyngeal angiofibroma]."
07/01/2002 - "To demonstrate the efficacy of external beam radiation therapy as a primary treatment modality for the management of patients with advanced juvenile nasopharyngeal angiofibroma (JNA). "
07/01/1990 - "Juvenile nasopharyngeal angiofibroma: efficacy of radiation therapy."

01/01/2020 - "Here, we describe single case review of a 14-year-old female who presented with an angiofibroma on the right nipple areolar complex, which was treated successfully with debulking and CO2 laser. "
12/01/1999 - "The purpose of this study was to evaluate the efficacy of CO2 laser resurfacing with flashscanner in the treatment of facial angiofibromas. "
11/01/2016 - "All reported an improvement in appearance of angiofibromas following treatment and that they would recommend CO2 laser ablation to others. "
11/01/2001 - "Treatment of angiofibromas with a scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up."
01/01/2021 - "All angiofibromas were removed with the use of a CO2 laser. "

09/01/2004 - "An interesting case of unilateral angiofibromas successfully treated with pulsed dye laser."
11/01/1993 - "Treatment of angiofibroma with the pulsed tunable dye laser."
07/01/2010 - "The technique of electrosurgery, pulsed-dye laser treatment, and AFR represents a new and safe therapeutic option for treating facial angiofibromas associated with TS."
07/01/2010 - "New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis."
12/01/1994 - "CO2, argon, and pulsed dye laser treatment of angiofibromas."

01/01/2008 - "[Efficacy of remote gamma-therapy in patients with juvenile angiofibroma of the base of the skull]."
05/01/2004 - "This study was undertaken to evaluate the incidence, clinical features and complications that may occur during the process of diagnosis and surgical therapy of angiofibromas outside the nasopharynx. "
11/01/2023 - "Hyftor: An Emerging Therapy For Facial Angiofibromas."
11/01/2023 - "Is There a Role for Adjuvant Therapy in Patients with Large Juvenile Nasopharyngeal Angiofibromas?"
01/01/2012 - "Although the use of nonsurgical therapies is described in the literature, surgery is currently considered the ideal treatment for juvenile angiofibroma. "

10/01/2019 - "Since the selection of laser devices can be limited for some institutions, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO2 device."
01/01/2018 - "Vascular laser treatment of angiofibromas, annual clinical monitoring and paraclinical monitoring every 3 years were proposed to the patient."
10/01/2014 - "Angiofibroma on cheek mucosa: a rare entity and its management with laser."
11/01/2013 - "We report a targeted topical and combination laser technique for treating the angiofibromas of TS in one patient. "
04/01/2003 - "Endoscopic laser-assisted excision of juvenile nasopharyngeal angiofibromas."